and chymotrypsin suggested that known DPP-IV inhibitory dipeptides could be released (Erhardt 52 et al., 2016) . Known DPP-IV inhibitory peptides were identified in a gastrointestinal digest of 53 camel milk proteins (Tagliazucchi, Shamsia & Conte, 2016) and tryptic camel milk protein 54
hydrolysates . However, camel milk protein hydrolysates may also 55 contain DPP-IV inhibitory peptides which have not been previously reported in the literature. 56
Identification of peptides within food protein hydrolysates generally involves several 57 fractionation steps which can be relatively time-consuming and in certain instances may not be 58 suitable for the optimum separation of selected bioactive peptides or lead to a loss of beneficial 59 peptide-peptide interactions (i.e., synergistic or additive effects) ( To date, most studies which have identified DPP-IV inhibitory peptides within complex mixtures 66 have arisen as a result of different fractionation steps (Nongonierma & FitzGerald, 2016b) . To 67 our knowledge, the application of QSAR as an in silico tool to screen DPP-IV inhibitory peptides 68 within complex camel milk protein hydrolysates has not been previously employed. The aim of 69 this study was to identify novel DPP-IV inhibitory peptide sequences within camel milk protein 70
hydrolysates. This was achieved by first selecting peptides possessing the features of DPP-IV 71 inhibitory peptides. These consisted of peptides containing F/I/L/W at the N-terminus, P/A at 72 position 2 and/or P at the C-terminus (Nongonierma & FitzGerald, 2013b , 2014a , 2016a ; 73 Tulipano, Faggi, Nardone, Cocchi & Caroli, 2015). The predicted DPP-IV inhibitory potential of 74 these peptides was then determined using a previously developed QSAR model (Nongonierma & 75 FitzGerald, 2016c). Selected synthetic peptide sequences, which were predicted to be potent 76 DPP-IV inhibitors and stable to gastrointestinal enzymes, were then analysed for their in vitro 77 DPP-IV inhibitory properties and their mode of inhibition was also studied. 
Enzymatic hydrolysis of camel milk proteins 91
Camel milk protein hydrolysates were produced with a commercial trypsin preparation (PTN 92 6.0S, Novozymes, Bagsvaerd, Denmark) as previously described in an earlier study 93 . Briefly, camel milk (2.5% (w protein/w)) was resuspended in 94 distilled water and incubated for 60 min in a water bath (Lauda E100, Lauda Brinkmann, Lauda-95 Königshofen, Germany) set at 50C. Subsequently, the pH was adjusted to 7.0 using 2 M NaOH 96 (VWR). Temperature, enzyme to substrate ratio (E:S) and hydrolysis time were as defined in 97 Supplementary Table S1 . At the end of each reaction, the enzyme was heat inactivated (90°C, 20 98 min) in a water bath. Two camel milk protein hydrolysates (H9 and H16), possessing potent 99 DPP-IV inhibitory activity (DPP-IV half maximal inhibitory concentration (IC 50 ) value of 0.52 100 and 0.66 mg mL -1 , respectively, Supplementary Table S1), were studied. In addition, one bovine 101 inhibitory peptides were searched for in all samples. DPP-IV inhibitory peptide features include 148 hydrophobic amino acids (F/I/L/W) at the N-terminus, P/A at position 2 and/or P at the C-149 terminus (Nongonierma & FitzGerald, 2013b , 2014a , 2016a Tulipano et al., 2015) . In a second 150 step, the DPP-IV inhibitory activity (IC 50 ) of the peptides having DPP-IV inhibitory features was 151 predicted using a QSAR model developed for DPP-IV inhibitory peptides (Nongonierma & 152 FitzGerald, 2016c MathWorks, Inc, Natick, MA, USA) as previously outlined (Nongonierma & FitzGerald, 2016c) . 156 Peptides were ranked in order of predicted DPP-IV inhibitory potency. Rank 1 and 35 were 162 attributed to the most and least potent DPP-IV inhibitory peptides, respectively (Table 1) . 163
Among the previous sequences, peptides which were stable to SGID (i.e., sequences identified 164 both in H9 and SGID_H9) were selected and synthesised (Genscript) for further confirmatory 165 studies. In addition, the location of candidate peptides within mature camel and bovine milk 166 protein sequences was determined. The protein sequences (α s1 -, α s2 -, β-and κ-CN as well as -167 lactoglobulin (-Lg) and -lactalbumin (-La)) were obtained from Uniprot. 168
DPP-IV inhibition assay 169
The DPP-IV inhibition assay was carried out in triplicate as outlined earlier (Nongonierma & 170 FitzGerald, 2013a). The peptides were dispersed in HPLC water at concentrations ranging from 171 2.5 to 1000 µM (final concentration) and IPI, the positive control at final concentrations ranging 172 from 37 × 10 -2 to 37 µM. Essentially, 25L of sample was pipetted onto a 96-well microplate 173 predicted DPP-IV inhibitory activity of the selected peptides was then determined using QSAR 218 (Nongonierma & FitzGerald, 2016c) . The selected peptides identified within H9, H16, H17, 219 SGID_H9 and SGID_CM are shown in Table 1 . As already outlined, the QSAR model employed 220
does not accurately provide a DPP-IV IC 50 value and furthermore the model is only applicable to 221 competitive DPP-IV inhibitory peptides. Therefore, results obtained by QSAR analysis only 222 allows ranking of peptides which are competitive inhibitors of DPP-IV (Nongonierma & 223 FitzGerald, 2016c). Consequently, the mode of DPP-IV inhibition of the peptides also needs to 224 be determined. In total, 35 camel milk protein-derived peptides possessing DPP-IV inhibitory 225 peptide features and predicted to be stable to SGID were selected (Table 1) . 226
Most of the peptides selected for their potential to act as DPP-IV inhibitors originate from CNs, 227 this may arise from the fact that CNs are the most abundant protein components of camel milk, 228 representing ~ 74% of the total protein content, with -CN representing 65% of the total CN 229 fraction (Hailu et al., 2016) . A number of these peptides (12) exist both within camel and bovine 230 milk protein sequences (Table 1) . These were generally released in the camel milk sample (H16) 231
and not the bovine milk sample (H17) during hydrolysis. However, most of the peptides 232 identified (23) within the camel milk protein hydrolysates were unique to camel milk proteins 233 (Table 1) . This was attributed to amino acid sequence differences between the proteins of the 2 234 species. 235
Of the peptides identified in Table 1 annotated MS/MS spectra for LPVP and MPVQA are illustrated in Supplementary Fig. S1 . 248
These peptides were synthetized and analysed for their in vitro DPP-IV inhibitory properties 249 (Table 2 ). The tryptic camel milk protein hydrolysate (H16), which was produced under the same 250 conditions (40C, 1.8% E:S and 218 min) as H17, the bovine milk protein hydrolysate, was 251 previously shown to be a more potent DPP-IV inhibitory hydrolysate than H17 (Nongonierma et 252 al., 2017) . Therefore, to better understand the role of milk species (camel vs. bovine) on the 253 DPP-IV inhibitory activity, 2 specific bovine milk peptides (ILDKVGINY (-La (f95-103)) and 254 YPVEPF (-CN (f114-119))) identified within H17 in our previous work (Nongonierma et (Table 2) . 262
In vitro DPP-IV inhibitory properties of camel milk peptides 263
The 14 peptides selected for synthesis were first evaluated for their ability to inhibit DPP-IV at 264 1000 µM (Table 2) LPVP is present both in camel and bovine β-CN (Fig. 1) . However, surprisingly, it was only 286 identified within H16 the camel milk protein hydrolysate but not in H17, the bovine milk protein 287 hydrolysate produced using the same hydrolysis conditions as H16. Nevertheless, larger 288 fragments containing LPVP, i.e., VLPVPQ and VLPVPQK, were identified both in H17 and 289 H16 (data not shown). The sequence where LPVP is located within β-CN is conserved between 290 the 2 species (Fig. 1) . In both camel and bovine β-CN the amino acids upstream (V) and 291 downstream (Q) of LPVP are the same. The reason why this peptide may be released from camel 292 but not bovine β-CN is not fully understood. The release of LPVP from camel β-CN does not 293 appear to be a random phenomenon as it was also identified in H9, another camel milk protein 294 hydrolysate generated with PTN 6.0S using different hydrolysis conditions (Table 1 and  295   Supplementary Table S1) . 296
In a previous study, selective release from camel (H16) but not bovine (H17) β-CN, was 297 observed for LPLPL and LPVPQ (Fig. 1) , 2 DPP-IV inhibitory peptides (Nongonierma et al., 298 2017) . LPVPQ is adjacent to a non-conserved area of β-CN with Q, the downstream amino acid 299 in camel β-CN, being substituted by K in bovine β-CN while the upstream amino acid (V) is the 300 same in both species (Fig. 1) . For LPLPL, the amino acids upstream (H) and downstream (L) of 301 the peptide are the same in camel and bovine β-CN (Fig. 1) . In bovine β-CN, the LC-MS/MS 302 results indicated that LPLPL was partly degraded to a shorter fragment corresponding to LPL 303 (Fig. 1) . These results seem to indicate that the enzyme selectivity towards substrates containing 304 similar peptide bond varies between camel and bovine milk proteins. This may arise from the 305 fact that camel milk proteins have been reported to be digested in a different manner by 306
gastrointestinal enzymes compared to bovine milk proteins. Camel whey proteins were reported 307 to be less digested by chymotrypsin and trypsin than bovine whey proteins. On the contrary, 308
camel CNs were more digested by trypsin/chymotrypsin than bovine CNs (Salami et al., 2008) . 309
These findings may be consistent with the observation that DPP-IV inhibitory sequences which 310 are present in both camel and bovine milk β-CN are not released to the same extent in the camel 311 (H16) and the bovine milk protein (H17) hydrolysates (Fig. 1) . To our knowledge, this is the first 312 time that species dependent substrates (camel vs. bovine) have been clearly shown to affect the 313 selectivity of peptide bond cleavage during enzymatic digestion of milk proteins. This in turn 314 may play an important role in releasing peptides possessing specific bioactivity. 315
MPVQA is only present within camel β-CN and not within bovine β-CN (Fig. 1) . Similar to 316
LPVP this peptide appears to arise as a result of a non-specific cleavage of β-CN or due to the 317 occurrence of side activities within the enzyme preparation (PTN 6.0S). According to their 318 cleavage specificity, trypsin and chymotrypsin, cleave at the C-terminal side of R/K and bulky 319 hydrophobic amino acids (F/K/W/Y), respectively (Godfrey, 1996) . Several peptides were 320 identified within the tryptic camel milk protein hydrolysates (H9 and H16, Table 1 This interaction with the active site is responsible for the inhibition of DPP-IV. The presence of 343 P at position 2 is important for DPP-IV inhibition as the activity of LPVP and MPVQA was 344 absent when these sequences were present as the precursor peptides VLPVP and AMPVQAVLP, 345 respectively, where both had DPP-IV IC 50 values > 1000 µM (Table 2) . 346
As already outlined, several known DPP-IV inhibitory peptides have already been identified 347 within the camel milk protein hydrolysates H9, H16, SGID_H9 and SGID_CM (Nongonierma etal., 2017) . The DPP-IV inhibitory peptides identified previously in camel milk protein 349 hydrolysates and for which an IC 50 value have been determined in the literature or in this study 350 are depicted on the sequence of camel β-CN (Fig. 1) substrates. As expected, YPVEPF and SPVVPF were cleaved by DPP-IV at the C-terminal side 420 of the penultimate P residue. The expected products of this reaction (i.e, YP and VEPF) were 421 identified for YPVEPF, while for SPVVPF only VVPF was identified (the expected reaction 422 products are SP and VVPF, Fig. 2) . In contrast, when IPI and LPVP were incubated with DPP-423 IV, no peptide degradation was observed (Fig. 2) , which may be attributed to the possibility that 424 the degradation products (I, PI, LP and VP) were below the limit of detection of the MS. and MPVQA) were competitive inhibitors of DPP-IV (Fig. 3 and Table 2 ). 443
Peptides possessing the structure of preferred DPP-IV substrates (i.e., P/A residues at position 2) 444 are generally thought to behave as competitive inhibitors of DPP-IV as they bind to its active site 445 (Rahfeld et al., 1991) . However, this was not the case for SPVVPF and YPVEPF herein, which 446
were mixed-type inhibitors of DPP-IV. Similar results have already been obtained in earlier 447 studies where peptides possessing a P at position 2 were also identified as mixed-type inhibitors 448 of DPP-IV (Nongonierma & FitzGerald, 2016c) . The reason for this mode of inhibition is 449 unclear. These DPP-IV substrates were hydrolysed to shorter entities (Fig. 2) , which may also be 450 
